In the study, usual treatment consisted of brief counselling and referrals for community treatment programs. Naltrexone intramuscular depot is licensed in the US for the treatment and prevention of relapse in people with opioid dependence who have undergone detoxification treatment. There are no development plans for this product in the EU.